Eikon Therapeutics, Inc.
For the period ended Aug 13, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 13, 2026 · Filed Aug 13, 2026
Use the contents to explore the available documents and sections.
EIKN$5.90+1.0%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · DRAFT
DRAFT
Officer. “Additional development programs to be reviewed at ESMO demonstrate our ability to execute global clinical trials across multiple indications. We remain focused on deploying capital toward opportunities that we believe have the potential to significantly enhance shareholder value over the next few years.”
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.